TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15684260
Drug: Morphine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine group (0.003% morphine)
Study: 10743823
Drug: Tramadol (200-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (200-400 mg/day)
Study: 8708983
Drug: Orally dissolving
Normalized name: MUCOTROL Sugar-free Orally Dissolving Wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally dissolving tablet (ODT) containing 99mTc‐labelled cholestyramine resin
Study: 8708983
Drug: 1.5 mL
Normalized name: Humulin 70/30 1.5 ML Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mL aqueous suspension of 99mTc‐labelled cholestyramine resin
Study: 8708983
Drug: Both dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosage forms (ODT and aqueous suspension)
Study: 1960302
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with recombinant tissue‐type plasminogen activator or urokinase
Study: 7139504
Drug: Inhaled powder
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled powder (200 micrograms)
Study: 7139504
Drug: Inhaled powder
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled powder (400 micrograms)
Study: 20679260
Drug: Systematic Treatment
Normalized name: Integrase Inhibitors, antiinfectives for systematic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic Treatment Selection (STS) for Psychodynamic Therapy (PDT)
Study: 20679260
Drug: Random Treatment
Normalized name: Nerandomilast
DrugBank: Nerandomilast (DB18237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random Treatment Selection (RTS) for Psychodynamic Therapy (PDT)
Study: 20679260
Drug: Systematic Treatment
Normalized name: Integrase Inhibitors, antiinfectives for systematic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic Treatment Selection (STS) for Cognitive-Behavioural Therapy (CBT)
Study: 20679260
Drug: Random Treatment
Normalized name: Nerandomilast
DrugBank: Nerandomilast (DB18237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random Treatment Selection (RTS) for Cognitive-Behavioural Therapy (CBT)
Study: 16368054
Drug: RSG 4
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RSG 4 mg/day (increased to 8 mg/day) + MET 1000 mg/day (total 1500 mg/day)
Study: 16368054
Drug: MET 500
Normalized name: cefetamet 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: MET 500 mg/day (increased to 2000 mg/day)
Study: 8521882
Drug: Carvedilol 25
Normalized name: carvedilol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 25 mg b.i.d for 2 weeks followed by 50 mg b.i.d for a further 2 weeks
Study: 8521882
Drug: Intravenous carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous carvedilol followed by oral carvedilol 50 mg b.i.d for 8 weeks
Study: 2677532
Drug: Aspirin, 80
Normalized name: Non-Aspirin, 80 mg/0.8 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 80 mg/day
Study: 29934249
Drug: 2 mA
Normalized name: Alpha 2 macroglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mA tDCS administered for 10 sessions of 20 minutes each on five consecutive days (two sessions per day)
Study: 29934249
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered for 10 sessions of 20 minutes each on five consecutive days (two sessions per day)
Study: 22430640
Drug: Streaming weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streaming weekly soap opera video episodes to smartphones
Study: 22430640
Drug: Weekly HIV
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly HIV risk reduction written messages to smartphones
Study: 18304620
Drug: Yttrium‐90‐labeled human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yttrium‐90‐labeled human milk fat globule 1 murine monoclonal antibody (90Y‐muHMFG1)
Study: 15830972
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment with medical and physical therapy
Study: 10484900
Drug: H2 receptor
Normalized name: Histamine H2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2 receptor antagonists (Group A)
Study: 9085534
Drug: Adjustable oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjustable oral appliances (OA)
Study: 7128187
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g glucosamine sulphate daily
Study: 7128187
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g ibuprofen daily
Study: 22425689
Drug: Microencapsulated Lactobacillus
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microencapsulated Lactobacillus reuteri NCIMB 30242 in yogurt, 5 × 10(10) CFU, twice/day for 6 weeks
Study: 15807452
Drug: Colloid bismuth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid bismuth subcitrate (CBS) 240 mg twice a day + amoxicillin 2 g/day and furozolidon 400 mg/day (subgroup 1a, n = 10)
Study: 15807452
Drug: Colloid bismuth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid bismuth subcitrate (CBS) monotherapy 240 mg twice a day (subgroup 1b, n = 20)
Study: 15807452
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice a day (group 2, n = 15)
Study: 9505333
Drug: Ultrasonic debridement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic debridement with 24% EDTA solution as irrigation agent
Study: 8475962
Drug: Acetaminophen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (10 micrograms/ml)
Study: 8475962
Drug: Acetaminophen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (100 micrograms/ml)
Study: 8475962
Drug: Indomethacin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (10 micrograms/ml)
Study: 3092657
Drug: Enprostil 70
Normalized name: enprostil
DrugBank: Enprostil (DB13824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprostil 70 micrograms twice daily
Study: 3092657
Drug: Enprostil 70
Normalized name: enprostil
DrugBank: Enprostil (DB13824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprostil 70 micrograms twice daily (in smokers)
Study: 3092657
Drug: Enprostil 35
Normalized name: enprostil
DrugBank: Enprostil (DB13824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprostil 35 micrograms twice daily (in smokers)
Study: 26233499
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg intraarticular triamcinolone acetonide
Study: 26233499
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg intraarticular triamcinolone acetonide
Study: 24264552
Drug: Pregabaline 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabaline 150 mg 1 hr before operation and 75 mg 12 hr after operation
Study: 24264552
Drug: Placebo empty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo empty capsule
Study: 18942248
Drug: Pethidine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine 1.5 mg/kg (Group P)
Study: 16798309
Drug: BioGlue (surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: BioGlue (surgical treatment and BioGlue)
Study: 16798309
Drug: Control (surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (surgical treatment only)
Study: 26579629
Drug: Computer-assisted cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted cognitive behavioral therapy for anxiety
Study: 22827782
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose zinc supplementation (50 mg elemental Zn sulfate daily)
Study: 22827782
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose zinc supplementation
Study: 17300591
Drug: DPP-IV inhibitors
Normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPP-IV inhibitors (e.g., vildagliptin, sitagliptin)
Study: 16392769
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid supplements (1,800 mg/day)
Study: 16392769
Drug: Diet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet therapy (control group)
Study: 11979054
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg cortisol intravenously
Study: 29548729
Drug: Hyperbaric-Oxygen Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric-Oxygen Therapy (HBOT) at 2.0 ATA for 60 sessions
Study: 29548729
Drug: Hyperbaric-Oxygen Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric-Oxygen Therapy (HBOT) at 2.0 ATA for 90 sessions
Study: 29548729
Drug: Hyperbaric-Oxygen Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric-Oxygen Therapy (HBOT) at 1.5 ATA for 60 sessions
Study: 29548729
Drug: Hyperbaric-Oxygen Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric-Oxygen Therapy (HBOT) at 1.5 ATA for 90 sessions
Study: 17325899
Drug: Pixantrone 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pixantrone 80 mg/m2, methylprednisolone 500 mg, cisplatin 25 mg/m2, cytarabine 2000 mg/m2
Study: 15049795
Drug: Sirolimus (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (1, 3, 9, or 15 mg/m(2))
Study: 11875681
Drug: 0.25% nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% nitroglycerin topically (administered in two daily applications for two weeks)
Study: 11875681
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (placebo)
Study: 28629540
Drug: Intranasal Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal Oxytocin (OXT) at a dose of 24 international units, administered 45-70 minutes prior to testing
Study: 25281353
Drug: Mendelian randomisation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mendelian randomisation analysis using SNPs related to 25(OH)D synthesis and metabolism.
Study: 21084392
Drug: Intraarterial ghrelin
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial ghrelin infusion (4.2 ng × kg(‐1) × min(‐1))
Study: 21084392
Drug: Intraarterial placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial placebo infusion
Study: 19335977
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil in combination with lamivudine for the first 12 weeks and adefovir dipivoxil only for the following 36 weeks
Study: 19335977
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil in combination with lamivudine for 48 weeks
Study: 17602082
Drug: Single high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high-dose chemotherapy (CE): one cycle of cisplatin 100 mg/m2, etoposide 375 mg/m2, and ifosfamide 6 g/m2 plus three cycles of high-dose carboplatin 1,500 mg/m2 and etoposide 1,500 mg/m2
Study: 17602082
Drug: Sequential high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential high-dose chemotherapy (CEC): three cycles of VIP plus one cycle of high-dose carboplatin 2,200 mg/m2, etoposide 1,800 mg/m2, and cyclophosphamide 6,400 mg/m2
Study: 15910203
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 0.25 mg/kg body weight
Study: 15910203
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 0.5 mg/kg body weight
Study: 12111764
Drug: Acetaminophen 650
Normalized name: acetaminophen 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 650 mg PO and diphenhydramine 25 mg IV
Study: 2037709
Drug: Rifampin 600
Normalized name: rifampin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 mg/d
Study: 31163689
Drug: Herbal mixture
Normalized name: Elm 65 mg in 5 mL ORAL SYRUP [AFRICAN SEA-COCONUT Herbal Mixture]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal mixture (700 mg daily)
Study: 31163689
Drug: Herbal mixture
Normalized name: Elm 65 mg in 5 mL ORAL SYRUP [AFRICAN SEA-COCONUT Herbal Mixture]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal mixture (700 mg daily) along with Clomiphene Citrate (CC) (50-150 mg for 3 months)
Study: 31163689
Drug: Clomiphene Citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene Citrate (CC) (50-150 mg for 3 months)
Study: 19267775
Drug: Torasemide-PR (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide-PR (10 mg daily for 4 days)
Study: 19267775
Drug: Torasemide-IR (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide-IR (10 mg daily for 4 days)
Study: 7731378
Drug: Climen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Climen (2 mg estradiol valerate and 1 mg cyproterone acetate)
Study: 7731378
Drug: Prempak-C (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prempak-C (0.625 mg conjugated equine estrogens and 0.15 mg norgestrel)
Study: 29429612
Drug: Lenalidomide 10
Normalized name: lenalidomide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 10 mg once daily (or 5 mg once daily for patients with creatinine clearance 40 to 60 mL/min)
Study: 26192892
Drug: Tamoxifen 40
Normalized name: tamoxifen 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 40 mg QD for 4 weeks in IMs
Study: 26192892
Drug: Tamoxifen 40
Normalized name: tamoxifen 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 40 mg QD for 4 weeks in PMs
Study: 26192892
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg QD for at least 4 weeks in EMs
Study: 11396752
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus fosfomycin (2 g fosfomycin twice daily for 5 days)
Study: 9430254
Drug: Thalidomide at
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide at 100 mg/day for 24 weeks
Study: 8487053
Drug: CPT-11 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT-11 administered as a 100 mg/m2 weekly intravenous infusion or 150 mg/m2 every 2 weeks
Study: 30802208
Drug: Topical NAC
Normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical NAC (3 mL, 300 mg)
Study: 30802208
Drug: Systemic NAC
Normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic NAC (200 mg/kg once daily)
Study: 30802208
Drug: Topical +
Normalized name: Topicale
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical + Systemic NAC (3 mL, 300 mg topical + 200 mg/kg systemic)
Study: 26599232
Drug: Pre-admission treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-admission treatment types
Study: 18155051
Drug: Anterior 3‐in‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior 3‐in‐1 femoral block with 30 mL of mepivacaine
Study: 18155051
Drug: Posterior psoas
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior psoas compartment block with 30 mL of mepivacaine
Study: 15577438
Drug: Accelerated radiotherapy
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated radiotherapy plus concurrent 96-hour infusional paclitaxel (40-120 mg/m2/cycle for the first 10 patients, 100 mg/m2/cycle for the subsequent 13 patients)
Study: 15577438
Drug: Accelerated radiotherapy
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated radiotherapy plus concurrent 96-hour infusional paclitaxel
Study: 10811493
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with carboplatin AUC 7 every 28 days for six courses (n = 81)
Study: 10811493
Drug: Observation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation and chemotherapy at progression (Control group, n = 81)
Study: 8697160
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg lisinopril
Study: 6125345
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg chlormezanone
Study: 6354600
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg chlormezanone
Study: 6354600
Drug: Chlormezanone (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormezanone (both doses)
Study: 29775246
Drug: Tramadol 400
Normalized name: tramadol hydrochloride 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 400 mg (therapeutic dose) on days 1-3, tramadol 100 mg and moxifloxacin-matched placebo on day 4, placebo on all 4 days
Study: 29775246
Drug: Tramadol 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 600 mg (supratherapeutic dose) on days 1-3, tramadol 150 mg and moxifloxacin-matched placebo on day 4
Study: 29775246
Drug: Placebo on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo on days 1-4 and moxifloxacin 400 mg on day 4
Study: 26337213
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dexamethasone (4 mg) and hyaluronidase (750 IU)
Study: 8092207
Drug: Ovesterin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovesterin 0.5 mg estriol vaginal pessaries
Study: 30669587
Drug: Quercetin (Q)
DrugBank: Quercetin (DB04216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (Q) 1000 mg/day
Study: 28318926
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg tranexamic acid followed by a continuous infusion of 1 mg/kg/h until the end of surgery
Study: 23648395
Drug: DASH diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DASH diet intervention (8 group and 3 individual sessions over 3 months, followed by monthly phone consultations for another 3 months)
Study: 10799374
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g AX-rich fiber
Study: 10799374
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g AX-rich fiber
Study: 4080297
Drug: recombinant interferon-alpha
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: recombinant interferon-alpha 2C monotherapy
Study: 30953768
Drug: Endotoxin injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endotoxin injection
Study: 27005961
Drug: Fish-oil supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil supplementation (1800 mg of eicosapentaenoic acid and docosahexaenoic acid per day for 6 months)
Study: 18940119
Drug: Conventional Interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Interferon 3 MIU, S/C, three times a week plus Ribavirin 800 to 1200 mg in divided doses daily for 12 weeks (Group-I, n=81)
Study: 18940119
Drug: Conventional Interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Interferon 3 MIU, S/C, three times a week plus Ribavirin 800 to 1200 mg in divided doses daily for 24 weeks (Group-II, n=81)
Study: 18940119
Drug: Conventional Interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Interferon 3 MIU, S/C, three times a week plus Ribavirin 800 to 1200 mg in divided doses daily for 24 weeks (Group-III, n=65)
Study: 15857840
Drug: Fluorouracil-based first-line
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil-based first-line chemotherapy in patients with advanced mucinous CRC
Study: 15857840
Drug: Fluorouracil-based first-line
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil-based first-line chemotherapy in patients with non-mucinous CRC (control group)
Study: 12551866
Drug: Nifedipine 30
Normalized name: nifedipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 30 to 60 mg/d
Study: 12551866
Drug: Nifedipine and
Normalized name: nifedipine and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine and cerivastatin combination
Study: 12551866
Drug: Cerivastatin 0.4
Normalized name: cerivastatin 0.4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.4 mg/d
Study: 9871860
Drug: Unoprostone isopropyl
Normalized name: Unoprostone Isopropyl
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unoprostone isopropyl 0.12% twice daily
Study: 9871860
Drug: Unoprostone isopropyl
Normalized name: Unoprostone Isopropyl
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unoprostone isopropyl 0.12% three times daily
Study: 7847298
Drug: Interferon-alpha (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha (6 million units three times/wk for 6 months) plus ursodeoxycholic acid (10 mg/kg/day for 9 months)
Study: 2140970
Drug: 1,500 mg
Normalized name: garlic 1,500 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,500 mg of acetyl-L-carnitine for 45 days
Study: 16931685
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (PAS at nonacupoints on shoulders)
Study: 7904489
Drug: rHuGM‐CSF at
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuGM‐CSF at a dose of 125 micrograms/m2/d by continuous intravenous infusion (group 2)
Study: 7904489
Drug: rHuGM‐CSF at
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuGM‐CSF at a dose of 250 micrograms/m2/d by continuous intravenous infusion (group 3)
Study: 8062862
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with a pause of 2-3 months
Study: 8062862
Drug: Continuous active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous active treatment without interruption
Study: 380427
Drug: Intravenous physostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous physostigmine (1.00 to 1.67 mg) administered at a rate of 0.5 mg/min every 4 min.